{"id":"0378084cf033","type":"article","url":"https://hartvaat.nl/2016/09/13/clopidogrel-versus-ticagrelor-bij-diabetes-na-pci-gerandomiseerde-trial/","title":"Clopidogrel versus ticagrelor bij diabetes na PCI: gerandomiseerde trial","title_en":"Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study (Clopidogrel High Dose Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients).","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog"],"tags":["credence-trial","soul-trial","trombocytenaggregatieremmers"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.116.023743","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.116.023743","authors":["Fabio Mangiacapra","Elena Panaioli","Iginio Colaiori","Elisabetta Ricottini","Angelo Lauria Pantano","Paolo Pozzilli","Emanuele Barbato","Germano Di Sciascio"],"significance":6,"published":"2016-09-13","source_date":"2016-09-13","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/"],"congress":"","summary_en":"This randomized comparison of clopidogrel versus ticagrelor for antiplatelet maintenance in diabetic PCI patients provided head-to-head data on these P2Y12 inhibitors in the diabetic population.","created":"2026-07-03T10:26:18Z","updated":"2026-07-03T13:25:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerandomiseerde vergelijking van clopidogrel versus ticagrelor voor antiplaatjesonderhoud bij diabetespatiënten behandeld met PCI. Onderzoekt de optimale P2Y12-remmerkeuze bij diabetes.","abstract_original":""}